Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ras Peptide Vaccine with IL-2 or GM-CSF for Solid Tumors
NCT00019331Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 1997
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TG01 in solid tumor, sponsored by National Cancer Institute. Started Oct 1997; status: completed.
02
Drugs
TG01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT00019331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019331.